EYPT (EyePoint Pharmaceuticals) Long-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Long-Term Debt?

EyePoint Pharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

EyePoint Pharmaceuticals's annual Long-Term Debt declined from Dec. 2021 ($36.56 Mil) to Dec. 2022 ($29.31 Mil) and declined from Dec. 2022 ($29.31 Mil) to Dec. 2023 ($0.00 Mil).

EyePoint Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for EyePoint Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Long-Term Debt Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

47.22

37.98

36.56

29.31

EyePoint Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

EyePoint Pharmaceuticals (NAS:EYPT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

EyePoint Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

PV3B:Germany PV3B:Germany

Address

480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Executives

Goran Ando	director
Wendy F Dicicco	director
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Nancy Lurker	director, officer: President and CEO	PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer	director	ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones	officer: SVP & Chief Commercial Officer	C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino	officer: Chief Medical Officer	4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu	director	ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine	officer: Chief Corp Dev.&Strat. Officer	C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p.	10 percent owner	21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis	director	3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension	10 percent owner	56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston	officer: Chief Financial Officer	124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis	director	1700 KENT AVENUE, WEST LAFAYETTE IN 46906